NCT01034579 - The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Relapsing Multiple Sclerosis

Interventions

OTHER

Blood sampling

Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.

OTHER

Blood sampling

Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.

Trial Locations (1)

Unknown

Please Contact U.S. Medical Information Located in, Rockland